Navigation Links
Mergent, Inc. Announces Changes to the HealthShares(TM) Composite, Enabling Technologies, Autoimmune-Inflammation, Cancer, Cardiology and Neuroscience Indexes
Date:5/6/2008

NEW YORK, May 6 /PRNewswire/ -- Mergent, Inc., administrator for the Healthshares(TM) Indexes, a series of 20 underlying indexes for the HealthShares(TM) Exchange Traded Funds, today announced the following changes with effect from the opening of trade on Friday, May 9, 2008: Masimo Corporation (Nasdaq: MASI) will replace Millennium Pharmaceuticals Inc (Nasdaq: MLNM) in the HealthShares(TM) Composite Index, Quest Diagnostics Inc (NYSE: DGX) will replace Millennium Pharmaceuticals Inc (Nasdaq: MLNM) in the HealthShares(TM) Enabling Technologies Index, Actelion (SWISS: ATLN) will replace Millennium Pharmaceuticals Inc (Nasdaq: MLNM) in the HealthShares(TM) Autoimmune-Inflammation Index, Fresenius SE (Frankfurt: FME) will replace Millennium Pharmaceuticals Inc (Nasdaq: MLNM) in the HealthShares(TM) Cancer Index, Actelion (SWISS: ATLN) will replace Millennium Pharmaceuticals Inc (Nasdaq: MLNM) in the HealthShares(TM) Cardiology Index, and Schwarz Pharma AG (Frankfurt: SRZ) will replace Millennium Pharmaceuticals Inc (Nasdaq: MLNM) in the HealthShares(TM) Neuroscience Index. Millennium is being acquired by Takeda Pharmaceutical Company Limited (Tokyo: 4502) through a cash tender offer.

The HealthShares(TM) Composite Index consists of the 80 largest companies, by market capitalization, that are engaged in healthcare, life sciences and/or biotechnology that are part of the 16 underlying HealthShares(TM) Indexes, selecting the top 5 companies in market capitalization from each of the Composite Eligible Indexes.

Companies included in the HealthShares(TM) Enabling Technologies Index provide technology products and/or services that enable and support the discovery, clinical development and manufacturing activities of pharmaceutical and biotechnology companies, including but not limited to genomics, proteomics, and high throughput screening.

Companies included in the HealthShares(TM) Autoimmune-Inflammation Index are engaged in the research, clinical development and/or commercialization of therapeutic agents for the treatment of inflammatory diseases such as osteoarthritis and autoimmune disorders including, but not limited to, rheumatoid arthritis, allergies, multiple sclerosis, psoriasis and lupus.

Companies included in the HealthShares(TM) Cancer Index are engaged in the research, clinical development and/or commercialization of therapeutic agents for the treatment of a wide variety of cancers.

Companies included in the HealthShares(TM) Cardiology Index are engaged in the research, clinical development and/or commercialization of therapeutic agents for the treatment of cardiological indications including, but not limited to, atherosclerosis, coronary artery disease, congestive heart failure, stroke, hypertension, thrombosis, and restenosis.

Companies included in the HealthShares(TM) Neuroscience Index are engaged in the research, clinical development and/or commercialization of therapeutic agents for the treatment of a wide variety of neurological and psychiatric disorders including, but not limited to, Alzheimer's, Parkinson's, Huntington's, schizophrenia, anxiety, depression, epilepsy, pain and sleep disorders.

About Mergent

Mergent, Inc., a Xinhua Finance company (TSE Mothers: 9399; OTC ADRs: XHFNY), is the preferred provider of business and financial data on global publicly listed companies. Headquartered in Fort Mill, SC and New York City with sales offices in key North American cities, Mergent also has a strong global presence with offices in London, Shanghai, Tokyo, Toronto and Sydney. Mergent's databases contain detailed equity, debt and corporate action information on over 15,000 U.S. public companies, 20,000 non-U.S. public companies and all U.S. municipal bonds.

For more than a century, Mergent has been providing solutions to clients in the investment management, academic, research and corporate information fields. Today, that unique experience is combined with leading-edge technology to form a robust, diverse product line that operates under Mergent's umbrella. These include Mergent's Dividend Achievers Indices -- the premier benchmark for long-term returns; Ford Equity Research -- a leading independent investment research firm; Mergent Online -- a powerful web-based research portal that provides critical business information to support daily research and analysis; Mergent Manuals, Handbooks and Investment Guides; in-depth municipal and corporate fixed-income data, as well as end-of-day evaluation pricing; EventsData -- providing real-time information on corporate actions, dividend payouts, news and updates directly to client desktops. For more information, please visit http://www.mergent.com and http://www.dividendachievers.com.


'/>"/>
SOURCE Mergent, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. WebMD Announces First Quarter Financial Results
2. HLTH Corporation Announces First Quarter Financial Results
3. U.S. Preventive Medicine Announces Investment Banking Team
4. The Lucian Leape Institute at the National Patient Safety Foundation Announces the Appointment of Two New Members
5. NUCRYST Announces First Quarter 2008 Financial Results
6. Mettler-Toledo International Inc. Announces Webcast of Presentation at Bank of America Healthcare Conference
7. NicOx Announces U.S. Phase 2a Results for PF-03187207 and Gives an Update on Continuing NO-prostaglandin Program
8. WuXi PharmaTech Announces Postponement of Proposed Follow-on Offering
9. Rigel Announces First Quarter 2008 Financial Results
10. BioForm Medical Announces Extension of Lock-Up Period
11. Healthcare Realty Trust Announces First Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... ... 03, 2016 , ... The Lymphoma Research Foundation (LRF) – ... serving the lymphoma community through a comprehensive series of education programs, outreach initiatives ... New York City, with long-time partners The Paul Foundation, on November 10, 2016. ...
(Date:12/4/2016)... ... December 03, 2016 , ... ... Entrepreneurial Company in the Dallas area” Tuesday evening at the 26th Annual SMU ... presented by SMU's Cox School’s Caruth Institute for Entrepreneurship. Dallas 100™, co-founded by ...
(Date:12/4/2016)... , ... December 04, 2016 , ... Responsible dental care ... must brush properly to achieve optimal results. This important necessity inspired an inventor from ... for a way to ensure that people break or avoid bad techniques of brushing ...
(Date:12/2/2016)... SAN DIEGO, Calif. (PRWEB) , ... December 02, 2016 , ... ... Recognition Event at the Hard Rock Hotel San Diego honoring the 2016 MPN Heroes—eight ... as myeloproliferative neoplasms (MPNs) by going above and beyond the standard of care, demonstrating ...
(Date:12/2/2016)... , ... December 02, 2016 , ... ... announces the launch of its 60-day free trial program for all of the ... make the offer a truly hassle free experience. , FlexiSpot’s unique desktop risers ...
Breaking Medicine News(10 mins):
(Date:12/4/2016)... 2016   Pairnomix, LLC, a genetic research company ... by the White House, today announced that findings from its ... of candidate therapies for a patient with epileptic encephalopathy caused ... presented at the 70 th Annual Meeting of the ... , December 2-6, 2016.  Pairnomix, unique process ...
(Date:12/4/2016)... , Dec. 3, 2016  Results from the Phase ... an anti-P-selectin antibody, reduced the median annual rate of ... placebo (1.63 vs 2.98, p=0.010) in patients with or ... the data are being featured in the official press ... Hematology (ASH) Annual Meeting and presented during the Plenary ...
(Date:12/4/2016)... Dec. 3, 2016  Findings from a Novartis ... CTL019, an investigational chimeric antigen receptor T cell ... young adult patients with B-cell acute lymphoblastic leukemia ... session at the 58th American Society of Hematology ... p.m.). The global Phase II study found that ...
Breaking Medicine Technology: